Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Lotrisone Warnings Should Be Milder, FDA Committee Says

Executive Summary

Schering-Plough Lotrisone labeling should sufficiently warn against use of the drug in children under 12 but should not be so severe that physicians who use it off label for valid reasons are intimidated, FDA's Dermatologics & Ophthalmics Advisory Committee said.
Advertisement

Related Content

FDA Limits Schering Lotrisone Indication, Approves Lotion Formulation
FDA Limits Schering Lotrisone Indication, Approves Lotion Formulation
Corticosteroid-Only Arm Worth Public Health Risk In Antifungal Trials - Cmte.
Corticosteroid-Only Arm Worth Public Health Risk In Antifungal Trials - Cmte.
Low-Dose Hydrocortisone/Antifungal Development Urged At FDA Committee
Low-Dose Hydrocortisone/Antifungal Development Urged At FDA Committee
Advertisement
UsernamePublicRestriction

Register

PS036321

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel